A pharmacological rationale for improved everolimus dosing in oncology and transplant patients

R. ter Heine*, N. P. van Erp, H. J. Guchelaar, J. W. de Fijter, M. E.J. Reinders, C. M. van Herpen, D. M. Burger, D. J.A.R. Moes

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

12 Citations (Scopus)
9 Downloads (Pure)


Aims: Everolimus is a drug from the class of mammalian target of rapamycin inhibitors used for both immunosuppressant and oncological indications. We postulate that there is room for improvement of dosing, as the optimal immunosuppressive dose in calcineurin-free regimens is unknown and since the once daily dosing regimen for oncological indications is often associated with treatment-limiting toxicity. Methods: We developed a mechanistic population pharmacokinetic model for everolimus in cancer and transplant patients and explored alternative dosing regimens. Results: We found that formulation did not influence bioavailability and that use of >20 mg prednisolone daily increased everolimus clearance. In transplant patients, the approved dose of 0.75–1 mg twice daily (BID) results in subtherapeutic trough levels (<6 μg l–1) and that a higher starting dose of 2.25–3 mg BID is required. Conclusion: For oncological indications, our results encourage the investigation of dosing everolimus 3.75 mg BID in terms of superiority in safety and noninferiority in efficacy.

Original languageEnglish
Pages (from-to)1575-1586
Number of pages12
JournalBritish Journal of Clinical Pharmacology
Issue number7
Early online date25 Mar 2018
Publication statusPublished - Jul 2018
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2018 The British Pharmacological Society


Dive into the research topics of 'A pharmacological rationale for improved everolimus dosing in oncology and transplant patients'. Together they form a unique fingerprint.

Cite this